Latest Multiple Myeloma Research Foundation Stories
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase I/II study of elotuzumab (also known as Huluc63), a humanized anti-CS1 monoclonal IgG1 antibody administered intravenously, in combination with VELCADE(R) (bortezomib) for Injection for the treatment of relapsed multiple myeloma.
The Multiple Myeloma Research Consortium (MMRC) today announced the addition of two Member Institutions.
New Indication Provides Treatment-Free Interval As an Option Media: International Myeloma Foundation Peggy Frank, 818-735-3591 Logo: http://myeloma.org/ The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US Food and Drug Administration (FDA) to expand the benefits of VELCADE(R) (bortezomib) for injection to a wider range of multiple...
Celgene Corporation David Gryska, 908-673-9059 Sr. Vice President and Chief Financial Officer or Brian P.
Celgene International Sarl (Nasdaq:CELG) announced that data presented today at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had received.
Researchers eager to test laboratory findings in patient trials.